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We propose a rational approach to the design of live virus vaccines against influenza infection by alteration of the influenza
A virus M2 protein, which is responsible for ion channel activity. Previously we demonstrated that a mutant A/WSN/33 (H1N1)
influenza virus with defective M2 ion channel activity did not show appreciable growth defects in cell culture, although its
growth was attenuated in mice (T. Watanabe, S. Watanabe, H. Ito, H. Kida, and Y. Kawaoka, 2001, J. Virol. 75, 5656–5662). Here,
we show that this M2 ion channel defective mutant virus, the M2del29-31, protected mice against challenge with lethal doses
of influenza virus, indicating the potential of incorporating this M2 alteration in a live influenza vaccine as one of theated vaINTRODUCTION
Influenza A virus is a highly infectious respiratory
pathogen of birds and mammals, including humans
(Wright and Webster, 2001). It often produces significant
morbidity and mortality in humans and domestic animals,
resulting in global economic burden. Current methods of
immunization against influenza A virus include paren-
teral administration of inactivated influenza virus vac-
cines, which generally show 70–90% efficacy in reducing
the incidence of clinical illness in healthy subjects, if the
antigenicities of the circulating strains of virus match that
of the vaccine strain (Cox and Subbarao, 1999). In some
instances, however, immunization with inactivated vac-
cines is associated with very low protection rates or
short protection periods, because mucosal immunity and
cytotoxic T cell response are limited. It may also be
associated with adverse reactions such as pain, tender-
ness, myalgia, and, rarely, anaphylactic reaction to
chicken egg proteins introduced during vaccine produc-
tion in embryonated eggs.
Another promising approach to vaccination is the use
of cold-adapted live-attenuated influenza viruses
(Maassab and Bryant, 1999). These vaccines have
shown considerable promise in ongoing clinical trials,
especially in young children, who are poor responders to
inactivated vaccines due to the lack of immune memory
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266of influenza virus (Belshe et al., 1998). However, prelim-
inary results indicate that live virus vaccines may not be
significantly more effective than the best inactivated vac-
cine, especially in adults (Edwards et al., 1994), leaving
room for further improvement.
We propose an alternative approach to the design of
live virus vaccines, one that relies on alteration of the
influenza A virus M2 protein, whose transmembrane
(TM) domain is responsible for the protein’s ion channel
activity (Duff and Ashley, 1992; Holsinger et al., 1994;
Pinto et al., 1992; Sugrue et al., 1990). M2 ion channel
activity functions at an early stage of the viral life cycle
between the steps of virus penetration and uncoating
(Helenius, 1992). Specific changes in the M2 protein TM
domain alter the kinetics and ion selectivity of the chan-
nel. An M2 mutant protein with deletions of residues from
positions 29 to 31 in the TM domain ameliorated func-
tional ion channel activity, as assayed by a two-electrode
voltage-clamp procedure (Holsinger et al., 1994). We pre-
viously showed that the M2del29-31 virus, which con-
tains the A/Udorn/72 (H3N2) M gene carrying this TM
mutation and the other genes from A/WSN/33 virus, did
not show appreciable growth defects in cell culture,
although its growth was attenuated in mice (Watanabe et
al., 2001). In mice infected with wild-type virus, nearly 104
plaque-forming units (PFU) of virus were present in the
nasal turbinates and nearly 107 PFU of virus were in the
lungs, while no virus was recovered from the nasal
turbinates of mice infected with this M2 mutant and 1 logattenuating mutations. © 2002 Elsevier Science (USA)
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less virus was found in the lungs. Here, we describe
experiments in which this M2 ion channel-defective mu-
tant protected mice against challenge with lethal doses
of influenza virus.
RESULTS
Attenuation of M2del29-31 virus in mice
Previously, we demonstrated that replication of
M2del29-31 virus in the lungs was more than 10-fold
lower than that of wild-type WSN-UdM virus and the
former was not recovered in nasal turbinates from any of
the infected mice with 2  103 PFU of WSN virus intra-
nasally (Watanabe et al., 2001). To further characterize
the attenuated phenotype of the M2del29-31 virus in
mice, we compared LD50 values of the M2del29-31 and
its parent WSN-UdM viruses and found that the LD50 of
the former was 6.3 log PFU, while that of the latter was
5.8.
Antibody responses of mice immunized with the
M2del29-31 virus
To test the efficacy of M2del29-31 virus as a vaccine,
we intranasally inoculated BALB/c mice with 2  103
PFU of the virus. Body weight was monitored daily for 2
weeks, and mice infected with this dose of M2del29-31
virus did not lose weight (data not shown). Two weeks
after infection, four mice were sacrificed to obtain sera,
trachea-lung washes, and nasal washes. Immunoglobu-
lin G (IgG) and IgA antibodies were measured in these
samples with an enzyme-linked immunosorbent assay
(ELISA) (Fig. 1). Both IgG and IgA values in nasal and
trachea-lung washes from mice immunized with the
M2del29-31 virus were higher than in control mice. The
IgA response was negligible in serum, but IgG produc-
tion was clearly higher in mice inoculated with M2del29-
31. Neither Ig response was appreciable in control mice.
Thus, the M2del29-31 virus lacking M2 ion channel ac-
tivity efficiently induced antibody responses in a murine
model.
Protective efficacy of the M2del29-31 virus
The efficacy of vaccination with the M2del29-31 virus
was assessed at 2 weeks, 1 month, or 3 months postim-
munization by intranasal challenge under anesthesia,
with 100 LD50 doses of wild-type WSN virus. Virus titers
were determined by titration on Madin–Darby canine
kidney (MDCK) cells, using lung samples collected from
four mice on Day 3 postchallenge. The remaining ani-
mals were observed for clinical signs and symptoms of
disease for 14 days after challenge. In contrast to the fate
of control mice, those immunized with the M2del29-31
virus were protected against lethal challenge with WSN
virus (Table 1). All mice in the M2del29-31 virus group
survived, even when challenged 3 months after vaccina-
tion. Moreover, their body weights were not appreciably
affected by virus challenge, in contrast to control groups,
whose weights decreased rapidly postchallenge (Fig. 2).
The lung titers from immunized mice after challenge with
a 100 LD50 dose of wild-type WSN virus were below the
limit of detection by plaque assay (less than 102 PFU/g),
in contrast to control mice, which had over 107 PFU in
lung tissue after the same WSN challenge (Table 1).
Thus, the M2del29-31 virus effectively protected mice
against lethal influenza virus infection.
DISCUSSION
Promising live virus vaccine candidates must satisfy
the following criteria: growth to high titers in a suitable
FIG. 1. Virus-specific antibodies in samples from vaccinated mice. Sera, trachea-lung washes, and nasal washes from four mice from each group
were obtained before virus challenge. IgG and IgA in the samples of individual mice were detected by ELISA, as described under Materials and
Methods. Results are expressed as the mean absorbances (SD) of undiluted samples (trachea-lung and nasal washes) or 1:100 diluted samples
(sera). Differences between responses to control and the M2del29-31 virus were tested for statistical significance by Student’s t test.
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preparative medium, attenuation in the host, genetic sta-
bility, and consistent immunogenicity. The M2del29-31
virus, despite having an apparent defective M2 ion chan-
nel activity, replicates efficiently in cell culture. It also
shows genetic stability and attenuation in mice (Wa-
tanabe et al., 2001) and was clearly immunogenic in our
animal model. Unlike inactivated virus, which did not
induce protective immunity in mice when intranasally
inoculated three times with 16 hemagglutinating units of
virus (equivalent to 108 particles; Desselberger, 1975)
(Watanabe et al., 2002), the M2del29-31 virus provided
complete protection to animals (Table 1). A similar level
of protection has also been shown with virus containing
alterations in NS1 protein (Talon et al., 2000). Thus, the
M2del29-31 virus has considerable potential for use in a
live vaccine preparation.
We previously demonstrated that the chimeric mutant
M2HATM virus, in which the M2 TM domain was re-
placed with that from the HA of WSN virus, was highly
attenuated in mice (Watanabe et al., 2001), although it
replicated reasonably well in cell culture. Use of this
chimeric virus as a live vaccine would greatly reduce the
likelihood of the emergence of revertant viruses. How-
ever, when tested as a vaccine in mice, the M2HATM
virus failed to protect any animals from lethal challenge
with WSN virus and failed to induce an immune re-
sponse in immunized mice (data not shown). These re-
sults indicate that the M2HATM virus cannot replicate in
mice, and hence, that the M2 TM domain is a vital
component of the influenza A virus life cycle in vivo. The
lack of replication, and thus protection, in mice of the
M2HATM virus underscores the necessity of introducing
attenuating, not abrogating, mutations in the vaccine
strain. Indeed, for attenuated live vaccines to be effec-
tive, they must replicate to a sufficient level to induce an
effective immune response, without causing severe dis-
ease symptoms. The LD50 of the M2del29-31 virus was
less than 1 log greater than that of the wild-type strain,
permitting sufficient replication for induction of protective
immunity, without causing significant disease symptoms,
e.g., loss of body weight.
Recently, we (Neumann et al., 1999) and others (Fodor
et al., 1999) established a reverse genetics system
for generating infectious influenza virus entirely from
cDNAs. The ability to manipulate the viral genome without
technical limitations has profound implications for the
study of viral life cycles and their regulation, the function
of viral proteins, and the molecular mechanisms of viral
TABLE 1









Controlc 0/4 7.5 0.1
M2del29-31 4/4 2d
1 Month
Control 0/4 7.4 0.1
M2del29-31 4/4 2d
3 Months
Control 0/4 7.2 0.1
M2del29-31 4/4 2d
a Mice were challenged intranasally, under anesthesia, with 100 LD50
doses of wild-type WSN virus at 2 weeks, 1 month, or 3 months
postvaccination. Virus titers were determined in lung tissue at 3 days
postchallenge.
b Mice were monitored for 14 days after challenge.
c Control mice were mock-vaccinated with phosphate-buffered saline.
d No virus was detected in the lungs from any of the infected mice
(less than 102 PFU/g). Significantly different from the control (P 0.001)
by Student’s t test.
FIG. 2. Body weights of immunized mice after challenge with wild-type virus. Control mice and mice immunized with the M2del29-31 virus lacking
M2 ion channel activity were challenged with 100 LD50 doses at 2 weeks, 1 month, or 3 months postvaccination. Values are mean weights (SD).
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pathogenicity—all of which are significant factors in the
control of influenza infection. Reverse genetics enables
one to modify cold-adapted vaccines or to produce dif-
ferent “master” influenza vaccine strains. Although they
have proven to be extremely stable in clinical trials (Cha
et al., 2000), cold-adapted vaccine strains possess a
limited number of amino acid changes, raising concern
over the emergence of virulent revertants (Herlocher et
al., 1993). Ideally, live-attenuated virus vaccines would
have multiple attenuating mutations in the genes that
encode internal proteins. NS1 mutant viruses are highly
attenuated in mice because they lack interferon antago-
nist activity while retaining the ability to induce protective
immunity against influenza virus challenge (Talon et al.,
2000). Hence, by combining attenuating mutations such
as those in viruses reported by Talon et al. (2000) and
ours, one could produce an improved master influenza
virus as a first step in the production of safe live influenza
vaccines. Continued progress in understanding the func-
tions of viral proteins should allow the introduction of
multiple mutations in live vaccine strains, in addition to
those in the NS and M genes, thereby reducing the
likelihood of revertant virus generation.
MATERIALS AND METHODS
Cells and viruses
MDCK cells were maintained in minimal essential me-
dium (MEM) containing 5% newborn calf serum at 37°C
in 5% CO2. WSN-UdM and M2del29-31 viruses, which
contain the M gene from the A/Udorn/72 (H3N2) virus
and the other genes from A/WSN/33 virus, were propa-
gated in MDCK cells (Watanabe et al., 2001).
Experimental infection
Four-week-old female BALB/c mice, anesthetized with
sevoflurane, were infected with approximately 2  106
PFU (in 50 l) of the WSN-UdM (wild-type) and
M2del29–31 viruses. Body weights of mice infected with
these viruses were monitored for 14 days after chal-
lenge.
Immunization and protection tests
BALB/c mice (4-week-old female) were intranasally
immunized with 2  103 PFU (in 50 l) of the M2del29-31
virus. On the second week, four mice were sacrificed to
obtain sera, trachea-lung washes, and nasal washes.
Two weeks, one month, or three months after the last
vaccination, immunized mice were challenged intrana-
sally, under anesthesia, with 100 LD50 doses of the wild-
type WSN virus. For determination of virus titers in lung,
tissues were harvested at Day 3 and were homogenized
and titrated on MDCK cells. The remaining animals were
observed for clinical signs and symptoms of infection for
14 days after challenge.
Detection of virus-specific antibody
Serum samples were examined for antibody by an
ELISA (Kida et al., 1982). In this assay, the wells were
coated with purified WSN virus after treatment with 0.05
M Tris–HCl (pH 7.8) containing 0.5% Triton X-100 and 0.6
M KCl at room temperature and diluted in PBS. After
incubation of virus-coated plates with test serum sam-
ples, bound antibody was detected with rabbit anti-
mouse IgA (Kirkegaard & Perry Laboratories Inc., Gaith-
ersburg, MD) and goat anti-mouse IgG (Boehringer
Mannheim, Germany) conjugated to horseradish perox-
idase.
ACKNOWLEDGMENTS
We thank Krisna Wells and Martha McGregor for excellent technical
assistance and John Gilbert for editing the manuscript. This work was
supported by Public Health Service research grants, by Grants-in-Aid
by the Ministry of Education, Culture, Sports, Science, and Technology
and by the Ministry of Health, Labor, and Welfare, Japan, and by the
Japan Science and Technology Corporation. T.W. is the recipient of
Research Fellowship of the Japan Society for the Promotion of Science
for Young Scientists. S.W. is the recipient of the Japan Society for
Promotion of Science Postdoctoral Fellowship for Research Abroad.
REFERENCES
Belshe, R. B., Mendelman, P. M., Treanor, J., King, J., Gruber, W. C.,
Piedra, P., Bernstein, D. I., Hayden, F. G., Kotloff, K., Zangwill, K.,
Iacuzio, D., and Wolff, M. (1998). The efficacy of live attenuated,
cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
N. Engl. J. Med. 338, 1405–1412.
Cha, T. A., Kao, K., Zhao, J., Fast, P. E., Mendelman, P. M., and Arvin, A.
(2000). Genotypic stability of cold-adapted influenza virus vaccine in
an efficacy clinical trial. J. Clin. Microbiol. 38, 839–845.
Cox, N. J., and Subbarao, K. (1999). Influenza. Lancet 354, 1277–
1282.
Desselberger, U. (1975). Relation of virus particles counts to the hem-
agglutininating activity of influenza virus suspensions measured by
the HA pattern test and by use of the photometric HCU method. Arch.
Virol. 49, 365–372.
Duff, K. C., and Ashley, R. H. (1992). The transmembrane domain of
influenza A M2 protein forms amantadine-sensitive proton channels
in planar lipid bilayers. Virology 190, 485–489.
Edwards, K. M., Dupont, W. D., Westrich, M. K., Plummer, W. D., Jr.,
Palmer, P. S., and Wright, P. F. (1994). A randomized controlled trial of
cold-adapted and inactivated vaccines for the prevention of influenza
A disease. J. Infect. Dis. 169, 68–76.
Fodor, E., Devenish, L., Engelhardt, O. G., Palese, P., Brownlee, G. G.,
and Garcia-Sastre, A. (1999). Rescue of influenza A virus from re-
combinant DNA. J. Virol. 73, 704–712.
Helenius, A. (1992). Unpacking the incoming influenza virus. Cell 69,
577–578.
Herlocher, M. L., Maassab, H. F., and Webster, R. G. (1993). Molecular
and biological changes in the cold-adapted “master strain” A/AA/6/60
(H2N2) influenza virus. Proc. Natl. Acad. Sci. USA 90, 6032–6036.
Holsinger, L. J., Nichani, D., Pinto, L. H., and Lamb, R. A. (1994).
Influenza A virus M2 ion channel protein: A structure-function anal-
ysis. J. Virol. 68, 1551–1563.
269DEFECTIVE M2 ION CHANNEL ACTIVITY INFLUENZA VACCINE
Kida, H., Brown, L. E., and Webster, R. G. (1982). Biological activity of
monoclonal antibodies to operationally defined antigenic regions on
the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7)
influenza virus. Virology 122, 38–47.
Maassab, H. F., and Bryant, M. L. (1999). The development of live
attenuated cold-adapted influenza virus vaccine for humans. Rev.
Med. Virol. 9, 237–244.
Neumann, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Gao, P.,
Hughes, M., Perez, D. R., Donis, R., Hoffmann, E., Hobom, G., and
Kawaoka, Y. (1999). Generation of influenza A viruses entirely from
cloned cDNAs. Proc. Natl. Acad. Sci. USA 96, 9345–9350.
Pinto, L. H., Holsinger, L. J., and Lamb, R. A. (1992). Influenza A virus M2
protein has ion channel activity. Cell 69, 517–528.
Sugrue, R. J., Bahadur, G., Zambom, M. C., Hall-Smith, M., Doug-
las, A. R., and Hay, A. J. (1990). Specific structure alteration of
the influenza haemagglutinin by amantadine. EMBO J. 9, 3469–
3476.
Talon, J., Salvatore, M., O’Neill, R. E., Nakaya, Y., Zheng, H., Muster, T.,
Garcia-Sastre, A., and Palese, P. (2000). Influenza A and B viruses
expressing altered NS1 proteins: A vaccine approach. Proc. Natl.
Acad. Sci. USA 97, 4309–4314.
Watanabe, T., Watanabe, S., Ito, H., Kida, H., and Kawaoka, Y. (2001).
Influenza A virus can undergo multiple cycles of replication without
M2 ion channel activity. J. Virol. 75, 5656–5662.
Watanabe, T., Watanabe, S., Gabriele, N., Kida, H., and Kawaoka, Y.
(2002). Immunogenicity and protective efficacy of replication-incom-
petent influenza virus-like particles. J. Virol. 76, 767–773.
Wright, P. W., and Webster, R. G. (2001). Orthomyxoviruses. In “Fields
Virology” (D. M. Knipe, and P. M. Howley, Eds.), Lippincott-Raven
Publishers, Philadelphia.
270 WATANABE ET AL.
